Ustekinumab‑aauz bulk supplier for pharma manufacturers

Ustekinumab‑Aauz 45 mg or 90 mg Suppliers & Bulk Manufacturers

Available Forms: Subcutaneous injection, Intravenous infusion

Available Strengths: 45 mg or 90 mg

Reference Brands: Stelara(US & EU); Otulfi (ustekinumab-srlf) is a biosimilar of Stelara

Ustekinumab-aauz blocks interleukins 12 and 23, reducing inflammation and immune response. It effectively treats psoriasis, psoriatic arthritis, and Crohn's disease. Benefits include sustained symptom relief, improved skin and joint health, and enhanced quality of life through targeted therapy when administered under medical supervision.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ustekinumab-aauz is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality compliant with GMP and MDR standards. In the US, FDA approval requires comprehensive clinical trial data and safety validation. In the EU, CE marking certifies conformity with MDR. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical efficacy data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective biologic therapies globally, supporting management of psoriasis, psoriatic arthritis, and Crohn’s disease for optimal patient outcomes.

Ustekinumab‑Aauz — third party manufacturing & bulk supply

Ustekinumab‑Aauz 45 mg or 90 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ustekinumab‑Aauz is supplied as Subcutaneous injection, Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ustekinumab‑Aauz listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ustekinumab‑Aauz →

Back to Listing

Frequently Asked Questions

Ustekinumab‑aauz is listed as Subcutaneous injection, Intravenous infusion in 45 mg or 90 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ustekinumab‑aauz is referenced against Stelara(US & EU); Otulfi (ustekinumab-srlf) is a biosimilar of Stelara. Reference brands are shown for identification only and remain the property of their respective trademark owners.